Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 101

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Phospholamban interactome in cardiac contractility and survival: A new vision of an old friend

Haghighi, Kobra, Bidwell, Philip, Kranias, Evangelia G. · 2014 · Journal of Molecular and Cellular Cardiology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.yjmcc.2014.10.005

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 69

  1. Kranias, 2012, Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome, Circ Res, 110, 1646, 10.1161/CIRCRESAHA.111.259754 · DOI · Paper page
  2. Steenaart, 1992, The phospholamban phosphatase associated with cardiac sarcoplasmic reticulum is a type 1 enzyme, Arch Biochem Biophys, 293, 17, 10.1016/0003-9861(92)90359-5 · doi:10.1016/0003-9861(92)90359-5
  3. Carr, 2002, Type 1 phosphatase, a negative regulator of cardiac function, Mol Cell Biol, 22, 4124, 10.1128/MCB.22.12.4124-4135.2002 · DOI · Paper page
  4. Pathak, 2005, Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1, Circ Res, 96, 756, 10.1161/01.RES.0000161256.85833.fa · DOI · Paper page
  5. Zhao, 2009, The anti-apoptotic protein HAX-1 is a regulator of cardiac function, Proc Natl Acad Sci, 106, 20776, 10.1073/pnas.0906998106 · DOI · Paper page
  6. Arvanitis, 2007, Histidine-rich Ca2+-binding protein interacts with sarcoplasmic reticulum Ca2+-ATPase, Am J Physiol Heart Circ Physiol, 293, H1581, 10.1152/ajpheart.00278.2007 · DOI
  7. Park, 2013, Targeted ablation of the histidine-rich Ca2+-binding protein (HRC) gene is associated with abnormal SR Ca2+-cycling and severe pathology under pressure-overload stress, Basic Res Cardiol, 108, 344, 10.1007/s00395-013-0344-2 · doi:10.1007/s00395-013-0344-2
  8. Vafiadaki, 2013, Identification of a protein phosphatase 1/phospholamban interactome that is regulated by cAMP-dependent phosphorylation, PLoS ONE, 8, e80867, 10.1371/journal.pone.0080867 · DOI
  9. He, 1997, Overexpression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation, J Clin Invest, 100, 380, 10.1172/JCI119544 · DOI · Paper page
  10. Ji, 2000, Disruption of a single copy of the SERCA2 gene results in altered Ca2+ homeostasis and cardiomyocyte function, J Biol Chem, 275, 38073, 10.1074/jbc.M004804200 · DOI
  11. Anderson, 2009, Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene, J Mol Cell Cardiol, 47, 180, 10.1016/j.yjmcc.2009.03.013 · DOI
  12. Heinis, 2013, Prominent heart organ-level performance deficits in a genetic model of targeted severe and progressive SERCA2 deficiency, PLoS ONE, 8, e79609, 10.1371/journal.pone.0079609 · DOI
  13. Louch, 2010, Sodium accumulation promotes diastolic dysfunction in end-stage heart failure following Serca2 knockout, J Physiol, 588, 465, 10.1113/jphysiol.2009.183517 · doi:10.1113/jphysiol.2009.183517
  14. Dash, 2001, Gender influences on sarcoplasmic reticulum Ca2+-handling in failing human myocardium, J Mol Cell Cardiol, 33, 1345, 10.1006/jmcc.2001.1394 · DOI · Paper page
  15. Kawase, 2008, Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure, J Am Coll Cardiol, 51, 1112, 10.1016/j.jacc.2007.12.014 · DOI · Paper page
  16. Jessup, 2011, Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure, Circulation, 124, 304, 10.1161/CIRCULATIONAHA.111.022889 · DOI · Paper page
  17. Kho, 2011, SUMO1-dependent modulation of SERCA2a in heart failure, Nature, 477, 601, 10.1038/nature10407 · DOI · Paper page
  18. Tilemann, 2013, SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure, Sci Transl Med, 5, 211ra159, 10.1126/scitranslmed.3006487 · DOI
  19. MacLennan, 1998, Sites of regulatory interaction between calcium ATPases and phospholamban, Ann N Y Acad Sci, 853, 31, 10.1111/j.1749-6632.1998.tb08254.x · DOI · Paper page
  20. Chen, 2006, Cross-linking of C-terminal residues of phospholamban to the Ca2+ pump in cardiac sarcoplasmic reticulum to probe spatial and functional interactions within the transmembrane domain, J Biol Chem, 281, 14163, 10.1074/jbc.M601338200 · DOI · Paper page
  21. Chen, 2007, Mechanism of reversal of phospholamban inhibition of the cardiac Ca2+-ATPase by protein kinase A and by anti-phospholamban monoclonal antibody 2D12, J Biol Chem, 282, 20968, 10.1074/jbc.M703516200 · DOI
  22. Hou, 2008, Phosphomimetic mutations increase phospholamban oligomerization and alter the structure of its regulatory complex, J Biol Chem, 283, 28996, 10.1074/jbc.M804782200 · DOI
  23. Pallikkuth, 2013, Phosphorylated phospholamban stabilizes a compact conformation of the cardiac calcium-ATPase, Biophys J, 105, 1812, 10.1016/j.bpj.2013.08.045 · DOI · Paper page
  24. Glaves, 2011, Phosphorylation and mutation of phospholamban alter physical interactions with the sarcoplasmic reticulum calcium pump, J Mol Biol, 405, 707, 10.1016/j.jmb.2010.11.014 · DOI · Paper page
  25. Kadambi, 1996, Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice, J Clin Invest, 97, 533, 10.1172/JCI118446 · DOI · Paper page
  26. Luo, 1994, Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation, Circ Res, 75, 401, 10.1161/01.RES.75.3.401 · DOI · Paper page
  27. Lorenz, 1997, Regulatory effects of phospholamban on cardiac function in intact mice, Am J Physiol, 273, H2826
  28. del Monte, 2002, Targeting phospholamban by gene transfer in human heart failure, Circulation, 105, 904, 10.1161/hc0802.105564 · DOI · Paper page
  29. Brittsan, 2000, Maximal inhibition of SERCA2 Ca2+ affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban, J Biol Chem, 275, 12129, 10.1074/jbc.275.16.12129 · DOI
  30. Ziolo, 2005, Adenoviral gene transfer of mutant phospholamban rescues contractile dysfunction in failing rabbit myocytes with relatively preserved SERCA function, Circ Res, 96, 815, 10.1161/01.RES.0000163981.97262.3b · DOI
  31. Schmitt, 2003, Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban, Science, 299, 1410, 10.1126/science.1081578 · DOI · Paper page
  32. Haghighi, 2003, Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human, J Clin Invest, 111, 869, 10.1172/JCI17892 · DOI · Paper page
  33. Haghighi, 2006, A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy, Proc Natl Acad Sci U S A, 103, 1388, 10.1073/pnas.0510519103 · DOI · Paper page
  34. Medeiros, 2011, Mutations in the human phospholamban gene in patients with heart failure, Am Heart J, 162, 1088, 10.1016/j.ahj.2011.07.028 · DOI
  35. van der Zwaag, 2012, Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy, Eur J Heart Fail, 14, 1199, 10.1093/eurjhf/hfs119 · DOI · Paper page
  36. Haghighi, 2012, The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase, J Mol Cell Cardiol, 52, 773, 10.1016/j.yjmcc.2011.11.012 · DOI · Paper page
  37. Minamisawa, 2003, Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy, Biochem Biophys Res Commun, 304, 1, 10.1016/S0006-291X(03)00526-6 · DOI
  38. Haghighi, 2008, A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids, Hum Mutat, 29, 640, 10.1002/humu.20692 · DOI
  39. Medin, 2007, Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN −42 C>G mutation, Eur J Heart Fail, 9, 37, 10.1016/j.ejheart.2006.04.007 · DOI
  40. Vafiadaki, 2007, Phospholamban interacts with HAX-1, a mitochondrial protein with anti-apoptotic function, J Mol Biol, 367, 65, 10.1016/j.jmb.2006.10.057 · DOI
  41. Chao, 2008, Hax1-mediated processing of HtrA2 by Parl allows survival of lymphocytes and neurons, Nature, 452, 98, 10.1038/nature06604 · DOI · Paper page
  42. Lam, 2013, Novel role of HAX-1 in ischemic injury protection: involvement of Hsp90, Circ Res, 112, 79, 10.1161/CIRCRESAHA.112.279935 · DOI
  43. Neumann, 1997, Increased expression of cardiac phosphatases in patients with end-stage heart failure, J Mol Cell Cardiol, 29, 265, 10.1006/jmcc.1996.0271 · DOI · Paper page
  44. Huang, 1976, Separation and characterization of two phosphorylase phosphatase inhibitors from rabbit skeletal muscle, Eur J Biochem, 70, 419, 10.1111/j.1432-1033.1976.tb11032.x · DOI · Paper page
  45. Picking, 1991, Fluorescence studies on the interaction of inhibitor 2 and okadaic acid with the catalytic subunit of type 1 phosphoprotein phosphatases, Biochemistry, 30, 10280, 10.1021/bi00106a028 · DOI
  46. Sakashita, 2003, Regulation of type 1 protein phosphatase/inhibitor-2 complex by glycogen synthase kinase-3beta in intact cells, J Biochem, 133, 165, 10.1093/jb/mvg020 · DOI
  47. Kirchhefer, 2005, Enhanced cardiac function in mice overexpressing protein phosphatase inhibitor-2, Cardiovasc Res, 68, 98, 10.1016/j.cardiores.2005.05.019 · DOI
  48. Yamada, 2006, Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy, FASEB J, 20, 1197, 10.1096/fj.05-5299fje · DOI
  49. El-Armouche, 2006, Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes, Biochem Biophys Res Commun, 346, 700, 10.1016/j.bbrc.2006.05.182 · DOI
  50. Rodriguez, 2007, Phosphorylation of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects of protein kinase A signaling in cardiac myocytes, Am J Physiol Heart Circ Physiol, 293, H762, 10.1152/ajpheart.00104.2007 · doi:10.1152/ajpheart.00104.2007
  51. Nicolaou, 2009, Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury, Circ Res, 104, 1012, 10.1161/CIRCRESAHA.108.189811 · DOI
  52. Pritchard, 2013, Active inhibitor-1 maintains protein hyper-phosphorylation in aging hearts and halts remodeling in failing hearts, PLoS ONE, 8, e80717, 10.1371/journal.pone.0080717 · DOI
  53. Fish, 2013, AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling, Circ Heart Fail, 6, 310, 10.1161/CIRCHEARTFAILURE.112.971325 · DOI
  54. Chen, 2008, A human polymorphism of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile response of cardiomyocytes to beta-adrenergic stimulation, FASEB J, 22, 1790, 10.1096/fj.07-097428 · DOI
  55. Chu, 2004, Phosphoproteome analysis of cardiomyocytes subjected to beta-adrenergic stimulation: identification and characterization of a cardiac heat shock protein p20, Circ Res, 94, 184, 10.1161/01.RES.0000107198.90218.21 · doi:10.1161/01.res.0000107198.90218.21
  56. Fan, 2005, Novel cardioprotective role of a small heat-shock protein, Hsp20, against ischemia/reperfusion injury, Circulation, 111, 1792, 10.1161/01.CIR.0000160851.41872.C6 · DOI · Paper page
  57. Dreiza, 2010, The small heat shock protein, HSPB6, in muscle function and disease, Cell Stress Chaperones, 15, 1, 10.1007/s12192-009-0127-8 · DOI
  58. Qian, 2011, Small heat shock protein 20 interacts with protein phosphatase-1 and enhances sarcoplasmic reticulum calcium cycling, Circ Res, 108, 1429, 10.1161/CIRCRESAHA.110.237644 · doi:10.1161/circresaha.110.237644
  59. Fan, 2005, Hsp20 and its cardioprotection, Trends Cardiovasc Med, 15, 138, 10.1016/j.tcm.2005.05.004 · DOI
  60. Qian, 2009, Blockade of Hsp20 phosphorylation exacerbates cardiac ischemia/reperfusion injury by suppressed autophagy and increased cell death, Circ Res, 105, 1223, 10.1161/CIRCRESAHA.109.200378 · DOI
  61. Nicolaou, 2008, Human mutation in the anti-apoptotic heat shock protein 20 abrogates its cardioprotective effects, J Biol Chem, 283, 33465, 10.1074/jbc.M802307200 · DOI
  62. Hofmann, 1989, Molecular cloning of a histidine-rich Ca2+-binding protein of sarcoplasmic reticulum that contains highly conserved repeated elements, J Biol Chem, 264, 18083, 10.1016/S0021-9258(19)84681-1 · DOI
  63. Sacchetto, 1999, Interaction of triadin with histidine-rich Ca2+-binding protein at the triadic junction in skeletal muscle fibers, J Muscle Res Cell Motil, 20, 403, 10.1023/A:1005580609414 · doi:10.1023/a:1005580609414
  64. Zhang, 1997, Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane, J Biol Chem, 272, 23389, 10.1074/jbc.272.37.23389 · DOI · Paper page
  65. Lee, 2001, Interaction of HRC (histidine-rich Ca2+-binding protein) and triadin in the lumen of sarcoplasmic reticulum, J Biol Chem, 276, 39533, 10.1074/jbc.M010664200 · doi:10.1074/jbc.m010664200
  66. Gyorke, 2004, The role of calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium, Biophys J, 86, 2121, 10.1016/S0006-3495(04)74271-X · DOI · Paper page
  67. Gregory, 2006, Histidine-rich Ca binding protein: a regulator of sarcoplasmic reticulum calcium sequestration and cardiac function, J Mol Cell Cardiol, 40, 653, 10.1016/j.yjmcc.2006.02.003 · DOI
  68. Arvanitis, 2008, The Ser96Ala variant in histidine-rich calcium-binding protein is associated with life-threatening ventricular arrhythmias in idiopathic dilated cardiomyopathy, Eur Heart J, 29, 2514, 10.1093/eurheartj/ehn328 · DOI
  69. Singh, 2013, Abnormal calcium cycling and cardiac arrhythmias associated with the human Ser96Ala genetic variant of histidine-rich calcium-binding protein, J Am Heart Assoc, 2, e000460, 10.1161/JAHA.113.000460 · doi:10.1161/jaha.113.000460

Cited by

See all 101

Metadata

Authors
Haghighi, K., Bidwell, P., & Kranias, E. G.
Venue
Journal of Molecular and Cellular Cardiology
Publisher
Elsevier BV
Published
2014-12
Volume
77
Pages
160-167
ISSN
0022-2828
Cited by
101
References
5
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
NIH (HL-26057, HL-64018)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phospholamban interactome in cardiac contractility and survival: A new vision of an old friend. https://app.cochat.ai/papers/10.1016/j.yjmcc.2014.10.005
The paper
Haghighi, K., Bidwell, P., & Kranias, E. G. (2014). Phospholamban interactome in cardiac contractility and survival: A new vision of an old friend. Journal of Molecular and Cellular Cardiology. https://doi.org/10.1016/j.yjmcc.2014.10.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.